
Fantastic presentation from @Benjamin_Trewin regarding his data on optimal therapeutic dosing of corticosteroids at #MOGAD onset delaying time to first relapse @ECTRIMS. Great audience discussions @syd_health @kids_research

MSBase is an international real-world Neuroimmunology registry open to all practicing neurologists and their healthcare teams.

Fantastic presentation from @Benjamin_Trewin regarding his data on optimal therapeutic dosing of corticosteroids at #MOGAD onset delaying time to first relapse @ECTRIMS. Great audience discussions @syd_health @kids_research

#ECTRIMS2024 | Welcome to the 1st day of the 40th Congress of ECTRIMS! Thank YOU for being a vital part of this journey. 📽️ Watch MS experts Prof. Tobias Sejbæk, Prof. Jette Frederiksen, and Prof. Melinda Magyari (@melindamagyari), present today’s Daily Highlights. 👇 👇 👇

🚨 LIVE in 15 minutes! Join Scientific Session 1 on the revised diagnostic criteria w/ MS experts, incl. @xmontalban, @Marcello_Moccia, @DrWBRO, @kuchling_j, Fiorella Guido, @held_fr, chaired by @MarTintore & @Calabre04804429. 🔗 Join here: bit.ly/3AXBzOQ

MSBase is 20 years old!! and holds >110,000 patient records. Dedicated clinicians all over the world contributes data with >110 papers, many that have changed clinical practice. We are so grateful to all the supporters of our mission to improve the lives of people with #MS.


Your roadmap for Autoimmune Encephalitis. A useful slide being shared from our UK Childhood Neuroinflammatory Disorders meeting, put together by Dr Michael Eyre.

📢🔥Take note! Data from the massive @MSBase_Registry dataset shows that secondary and primary progressive MS disease differ in disease onset and course. This is super important to consider when studying disease modifying therapies. https://t.co/xhm0d5sbkI @izanne_roos

Fantastic catching up with friends &colleagues from the #BigMS data registries. Collectively, we manage ~300,000 patient records. “Harmonise the people, harmonise the data” @melindamagyari @dhorakova @TrojanoMaria @JiDrahota @VukusicS @MSBase_Registry @janhillert and many more!

Festive greetings and a joyous Christmas from the MSBase Management team, to our amazing MSBase Ops Team, SLG committees, Board and valued Members - wishing you all a safe and happy holiday season.

New published data @MonashCCS @Alfred_Research @HelmutButz @MSBase_Registry to support clinical decision making for patients with #MultipleSclerosis who need to switch #treatment to fully control their disease. Read more👇 monash.edu/medicine/news/lat…

Is HSCT really that good? This analysis at #ECTRIMS2022 (unrandomized) found HSCT is better than gilenya but similar in efficacy to ocrevus and tysabri (in relapses, disability progression), though improvement was more common with HSCT. ectrims2022.abstractserver.c…

🌷Late breaking news at #ECTRIMS2022 @Iamsterdam Surprising or not? Propensity matched study of #HSCT versus #Natalizumab in #progressive #MS revealed no difference in efficacy. Early treatment best, applies to both💡

Izanne Roos presenting a non-inferiority study of ocrelizumab and rituximab on behalf of the @MSBase_Registry and the Danish registry

Kalincik @MSBase_Registry study: Propensity-matched #progressive #MS patients treated with AHSCT or natalizumab. No difference on relapse rates and disability progression. #ECTRIMS2022

Visiting the hard working team at the @MSBase_Registry booth at #ECTRIMS2022 thank you to Charlotte Sartori, Pam Farr, Rein Moore, and Dusko Stupar for their amazing work on the operations team making the magic happen 🙌🏻

Made it into the pregnancy session in time for a really relevant talk by Annika Anderson - low transfer of CD20 molecules into mature breast milk (ie post colostrum) with infant dose <1%